Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-19 (Fujian Medical University)
- Development stage
- Unknown
- Lead developer
- Fujian Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CART-19 (Fujian Medical University) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen. Developed by Fujian Medical University, this cell therapy is primarily investigated for patients with CD19-positive acute lymphoblastic leukemia (ALL), particularly those who are minimal residual disease (MRD) positive. The mechanism involves the genetic modification of a patient's T cells to express a CAR that identifies and binds to CD19 on B-cell surfaces, triggering T-cell mediated cytotoxicity against the leukemic cells. This specific program aims to assess the safety and efficacy of the therapy in preventing relapse in high-risk patients defined by MRD+ status.
- Other names
- CD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsCART19CART-19CART 19CART-19-Fujian Medical University-acute lymphoblastic leukemiaCART19-Fujian Medical University-acute lymphoblastic leukemiaCART 19-Fujian Medical University-acute lymphoblastic leukemia
02
Targets
Beyond the preview
Go deeper on CART-19 (Fujian Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-19 (Fujian Medical University).